Cargando…

What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection

The linchpin of precision medicine is molecular genetic and genomic testing. Molecular biomarkers are important for establishing precise diagnoses and for predicting therapeutic responses that enable cancer patients to receive personalized and targeted treatment. Below are highlights of the current...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Guoli, Tsang, Patricia C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pathologists and the Korean Society for Cytopathology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601954/
https://www.ncbi.nlm.nih.gov/pubmed/34788978
http://dx.doi.org/10.4132/jptm.2021.09.01
_version_ 1784601469184376832
author Chen, Guoli
Tsang, Patricia C.
author_facet Chen, Guoli
Tsang, Patricia C.
author_sort Chen, Guoli
collection PubMed
description The linchpin of precision medicine is molecular genetic and genomic testing. Molecular biomarkers are important for establishing precise diagnoses and for predicting therapeutic responses that enable cancer patients to receive personalized and targeted treatment. Below are highlights of the current considerations in next generation sequencing (NGS) panel selection, and in molecular testing of solid tumors of the lung, digestive system, thyroid and soft tissue.
format Online
Article
Text
id pubmed-8601954
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Society of Pathologists and the Korean Society for Cytopathology
record_format MEDLINE/PubMed
spelling pubmed-86019542021-12-01 What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection Chen, Guoli Tsang, Patricia C. J Pathol Transl Med Newsletter The linchpin of precision medicine is molecular genetic and genomic testing. Molecular biomarkers are important for establishing precise diagnoses and for predicting therapeutic responses that enable cancer patients to receive personalized and targeted treatment. Below are highlights of the current considerations in next generation sequencing (NGS) panel selection, and in molecular testing of solid tumors of the lung, digestive system, thyroid and soft tissue. The Korean Society of Pathologists and the Korean Society for Cytopathology 2021-11 2021-11-12 /pmc/articles/PMC8601954/ /pubmed/34788978 http://dx.doi.org/10.4132/jptm.2021.09.01 Text en © 2021 The Korean Society of Pathologists/The Korean Society for Cytopathology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Newsletter
Chen, Guoli
Tsang, Patricia C.
What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
title What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
title_full What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
title_fullStr What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
title_full_unstemmed What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
title_short What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
title_sort what’s new in molecular genetic pathology 2021: solid tumors and ngs panel selection
topic Newsletter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601954/
https://www.ncbi.nlm.nih.gov/pubmed/34788978
http://dx.doi.org/10.4132/jptm.2021.09.01
work_keys_str_mv AT chenguoli whatsnewinmoleculargeneticpathology2021solidtumorsandngspanelselection
AT tsangpatriciac whatsnewinmoleculargeneticpathology2021solidtumorsandngspanelselection